Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility and Efficacy of dose-adjusted melphalan + prednisone + bortezomib (MPV) in elderly multiple myeloma
2013-000320-33Phase 2Active
- Sponsor
- HOVON
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan, prednisone and bortezomib in multiple myeloma (MM), sponsored by HOVON. Primary endpoint: Discontinuation rate. Started Jul 2013; status: active.
02
Drugs
melphalanprednisonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-000320-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000320-33.